MGIM
BMRN icon

M&G Investment Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

M&G Investment Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,392
Closed -$122 – 453
2020
Q4 		$122 Sell
1,392
-11,772
-89% -$933K ﹤0.01% 439
2020
Q3 		$1M Buy
13,164
+11,772
+846% +$1.19M 0.01% 294
2020
Q2 		$171K Buy
+1,392
New +$138K ﹤0.01% 393

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

M&G Investment Management's BMRN Position: Q1 2021 in Review

M&G Investment Management sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2021, closing a stake of 1,392 shares — an estimated $122 sold.

M&G Investment Management first reported a position in BMRN in Q2 2020 and held it in 3 quarters. The position peaked at $1M in Q3 2020. 530 funds tracked by Wall St. Rank hold BMRN as of Q1 2021.

  • M&G Investment Management reported no remaining BioMarin Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • M&G Investment Management sold 1,392 BioMarin Pharmaceuticals shares in Q1 2021, an estimated $122.
  • M&G Investment Management first reported a position in BioMarin Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • M&G Investment Management's BioMarin Pharmaceuticals position peaked at $1M in Q3 2020.
  • 530 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2021.

Based on M&G Investment Management's 13F filing for Q1 2021, filed 12 May 2021.